Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

The dispersion here is extreme: MRNA (+50.11%) and TEM (+42.86%) both closed essentially on their highs (98.67% and 99.15% of range), while KPTI (-39.95%), QURE (-27.76%) and CDXS (-25.07%) anchored the other tail. Options markets misjudged both directions. Realized/implied ratios above 2x — SYK 3.44x, EBS 3.37x, MRNA 3.17x, TEM 2.97x, AMGN 2.42x, STIM 2.31x — mark names where actual movement badly outran what was priced in; SYK is the standout, falling 19.46% and closing at just 4.39% of its range with an -18.19% period return against only 32.57% implied vol.

The reverse shows up in the highest-IV names: CDXS (310.16% implied, 0.37x), DBVT (246.68%, 0.31x), QURE (142.68%, 0.78x) and ADUS (0.61x) all delivered far less movement than priced, even while declining. XLV, at 0.71x with 15.24% realized vol, confirms index-level calm masking single-name chaos.

Closing location skewed bearish: THC (0.58%), CVS (3.93%), SYK (4.39%), ABT (5.45%), CI (6.60%) and CNC (7.88%) all finished near period lows.

Broader Market Context

Differential behavior within the sector. This was not a sector moving as one. XLV's -5.37% range and 15.24% realized volatility sit far below the constituent names, which is the signature of high internal dispersion rather than a directional sector trade. Three groupings pulled apart sharply:

• Managed care / services — UNH -9.97%, CI -9.34%, CNC -12.04%, HUM -12.11%, CVS -14.21%, THC -8.84% — a remarkably tight cluster of double-digit-ish declines, most closing near range lows.
• Large-cap pharma — ABBV +9.17%, MRK +7.90%, GILD +7.88%, LLY +7.59% — positive ranges with modest realized vol (roughly 20-25%), behaving like defensive ballast.
• Biotech and small-cap — MRNA and TEM up 40-50%, against KPTI, QURE, CDXS, DBVT and MGNX down 19-40%, with realized vols from 47% to 114%.

Rotation vs. idiosyncratic. The uniformity of the managed-care declines looks more like a sub-sector de-rating than coincidence — consistent with repricing of cost-trend, utilization or reimbursement assumptions that would affect insurers collectively. By contrast, the biotech tails are almost certainly idiosyncratic: 3x realized/implied ratios and closes at 98-99% of range in MRNA and TEM are the shape left by discrete, binary outcomes, not flows. With stable large-cap pharma alongside a punished services complex, this does not read as a clean risk-off rotation *into* healthcare, nor a wholesale rotation out.

Plausible current drivers. Without asserting specific events, the pattern is consistent with several live themes: ongoing policy and reimbursement uncertainty around government-funded coverage, which disproportionately hits insurers and hospitals; continued investor differentiation between obesity/oncology-levered large caps and the rest of pharma; and a clinical and regulatory calendar that produces the binary dispersion seen in the small-cap biotech names. AMGN's 2.42x vol surprise and SYK's 3.44x suggest even mega-cap healthcare carried unpriced event risk. The collapse in realized-versus-implied for the triple-digit-IV names (CDXS, DBVT) likely reflects expensive optionality decaying rather than resolving.